In this analysis of a prospective imaging trial, we aimed to explore the role of IL-6 plasma levels during chemoradiation as a potential surrogate for PET imaging-based tumor hypoxia dynamics in HNSCC patients. Here, IL6 is linked to head and neck squamous cell carcinoma.